Natixis Aurinia Pharmaceuticals Inc. Transaction History

Natixis

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	SELL	$4.93 - $9.31 $137,532 - $259,721	-27,897 Reduced 35.49%	50,717 $254,000
Q4 2023 Feb 13, 2024	SELL	$7.13 - $9.49 $1.55 Million - $2.06 Million	-217,541 Reduced 73.46%	78,614 $706,000
Q3 2023 Nov 14, 2023	BUY	$7.77 - $12.27 $263,395 - $415,940	33,899 Added 12.93%	296,155 $2.3 Million
Q2 2023 Aug 11, 2023	SELL	$8.96 - $11.69 $8.63 Million - $11.3 Million	-963,231 Reduced 78.6%	262,256 $2.54 Million
Q1 2023 May 12, 2023	BUY	$5.94 - $11.27 $1.49 Million - $2.82 Million	250,544 Added 25.7%	1,225,487 $13.4 Million
Q4 2022 Feb 24, 2023	BUY	$4.11 - $8.14 $1.63 Million - $3.24 Million	397,567 Added 68.86%	974,943 $4.21 Million
Q4 2022 Feb 13, 2023	BUY	$4.11 - $8.14 $1.85 Million - $3.66 Million	449,431 Added 351.27%	577,376 $2.49 Million
Q3 2022 Nov 14, 2022	SELL	$6.66 - $12.39 $5.81 Million - $10.8 Million	-872,055 Reduced 87.21%	127,945 $977,000
Q1 2022 May 13, 2022	BUY	$10.05 - $22.48 $5.03 Million - $11.2 Million	500,000 Added 100.0%	1,000,000 $12.4 Million
Q4 2021 Feb 14, 2022	BUY	$17.78 - $33.08 $8.89 Million - $16.5 Million	500,000 New	500,000 $11.4 Million

209

58.7M

1.14M

1.51M

Ticker AUPH
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 141,892,000
Market Cap $1.15B
Description
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license...

Get notified when there are updates to the investment portfolio of Natixis, based on Form 13F filings with the SEC.

Stay updated on Natixis with notifications on news.